INTERVIEWS

Nima Nejad Shiraz, VP of Finance & Operations at Tribeca Companies and COO with Spot-On Sciences, discusses the next generation of Dried Blood Spot (DBS) sample collection, and their partnering with Tribeca Companies to conduct an expansion of the company’s activities into new global markets.

As of June 11, 2019, Merck’s KEYTRUDA is now FDA approved for first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma as monotherapy for patients whose tumors express PD-L1 (CPS ≥1) or in combination with platinum and fluorouracil (FU) regardless of PD-L1 expression. Returning guest Dr. Danny Rischin, Director of the Department of Medical Oncology, Peter MacCallum Cancer Centre (Melbourne, Australia) discusses the final analysis of the Phase 3 KEYNOTE-048, KEYTRUDA study, which was presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.

Dr. Gerard Clum, D.C., Board Member of the Foundation for Chiropractic Progress, addresses the issues surrounding neck manipulation and strokes. There have been numerous medical studies showing there is no causal link between strokes and chiropractic care. The latest study, published in the Annals of Medicine on April 6, 2019, concludes that “manual therapy does not result in an increased risk of cervical artery dissection or CAD.

Dr. Paul MacKoul, one of the founders of The Center for Innovative GYN Care® (CIGC), discusses recent research that showed complex GYN issues are going undiagnosed among women around the world. The study, conducted by CIGC, collected 5 years of data from over 1,500 hysterectomy patients and nearly 1 thousand myomectomy patients who had surgeries at CIGC. He also talks about the laparoscopy techniques, DualPortGYN® and LAAM-BUAO® that have been perfected by CIGC.

Doron Youngerwood, Director of Marketing at SysAid® Technologies, discusses their IT service management (ITSM) solution software that provides a suite of tools that increases efficiency and improves patient care.

Mike Davis, Head of Neurology for UCB, a global biopharmaceutical company in the U.S., discusses the recent FDA approval of NAYZILAM® (midazolam) for the short term nasal treatment of seizure clusters, the company’s seizure portfolio, and the company’s commitment to the epilepsy community.

John Incledon, President of Hisamitsu America (the makers of Salonpas patches), discusses the Centers for Disease Control’s recent recommendation for physicians to consider the use of safer topical analgesics as the first line treatment for chronic pain.

Ebele Mbanugo of Lagos, Nigeria, grand prize winner of the 2018 C3 (Changing Cancer Care) Prize, discusses her work, where she created a culturally-relevant and easy-to-understand digital audio series about breast cancer for patients in Nigeria. She also operates Run For A Cure Africa, a non-profit organization created to eradicate breast cancer in Africa. She is determined in her mission to help erase the stigma of breast cancer treatment in her society through education. Learn more and submit an idea to the C3 Prize which will award $200,000 in total funds and resources to help winners further advance their ideas:

Susan Sheena, a mother of 4 boys, including a son diagnosed with schizophrenia at age 20, talks about her experience, what she wished she had known going into it and advice for other parents/patients to help better navigate a diagnosis.

Returning guest Dr. Alejandro Badia, founder of OrthoNOW® orthopedic urgent care centers, discusses innovations in treating tennis elbow and the newest treatment option for an arthritic thumb (BioPro® Modular Thumb Implant). For more information, visit www.drbadia.com.